Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medicare Value-Pricing Options Vary Widely In Part B Payment Experiment

Executive Summary

One option from CMS would adjust coinsurance to steer beneficiaries toward 'higher-value' drugs while other possible arrangements relate more directly to reducing Medicare payments.

You may also be interested in...



Medicare's Foreign Price Bench-marking Will Only Hurt Bad Negotiators, HHS's Azar Argues

President Trump touts CMS proposal that would peg Part B prices to an international index in the hopes of lowering US costs; industry calls it foreign price controls and warns it will hinder access.

Part B's Foreign Price Bench-marking Will Only Hurt Bad Negotiators, HHS's Azar Argues

President Trump touts CMS proposal that would peg Part B prices to an international index in the hopes of lowering US costs; industry calls it foreign price controls and warns it will hinder access.

ICER Value Assessments Could Provide US Standard, Payers, Providers Tell HHS

Comments to HHS on the Trump Administration’s US drug pricing blueprint recommend that cost effectiveness analyses by the Institute for Clinical and Economic Review could help promote value-based pricing.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS057509

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel